Progyny, Inc. (PGNY)

US — Healthcare Sector
Peers: OMCL  SDGR  TDOC  TXG  OMDA  UFPT  ALVO  PHR  GDRX  SEM 

Automate Your Wheel Strategy on PGNY

With Tiblio's Option Bot, you can configure your own wheel strategy including PGNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PGNY
  • Rev/Share 14.4808
  • Book/Share 6.0049
  • PB 4.2082
  • Debt/Equity 0.0495
  • CurrentRatio 2.6966
  • ROIC 0.0841

 

  • MktCap 2178568497.0
  • FreeCF/Share 2.2176
  • PFCF 11.4543
  • PE 40.7973
  • Debt/Assets 0.0335
  • DivYield 0
  • ROE 0.1155

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade PGNY KeyBanc Capital Markets Sector Weight Overweight -- $30 Nov. 12, 2025
Upgrade PGNY Leerink Partners Market Perform Outperform -- $28 July 8, 2025
Downgrade PGNY JMP Securities Mkt Outperform Market Perform -- -- Sept. 19, 2024

News

Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results Report
PGNY
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, will report its financial results for the quarterly period and full year ended December 31, 2024, after the close of the market on Thursday, February 27, 2025. The company will host a conference call at 4:45 p.m.

Read More
image for news Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2024 Results Report
Kuehn Law Encourages Investors of Progyny, Inc. to Contact Law Firm
PGNY
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Read More
image for news Kuehn Law Encourages Investors of Progyny, Inc. to Contact Law Firm

About Progyny, Inc. (PGNY)

  • IPO Date 2019-10-25
  • Website https://www.progyny.com
  • Industry Medical - Healthcare Information Services
  • CEO Peter Anevski
  • Employees 675

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.